56547-82-1

Usage

Uses

Used in Pharmaceutical Synthesis:
2-Cyclohexyl-5-methyl-2H-pyrazol-3-ylamine is used as an intermediate in the pharmaceutical industry for the synthesis of various drugs. Its unique structure allows it to be incorporated into the development of new medicinal compounds, potentially leading to innovative treatments for a range of health conditions.
Used in Agrochemical Production:
In the agrochemical industry, 2-Cyclohexyl-5-methyl-2H-pyrazol-3-ylamine is utilized as an intermediate in the production of pesticides and other agricultural chemicals. Its role in these applications contributes to the development of more effective and targeted agrochemicals to protect crops and enhance agricultural productivity.
Used in Coordination Chemistry:
2-Cyclohexyl-5-methyl-2H-pyrazol-3-ylamine is used as a ligand in coordination chemistry, where it forms complexes with metal ions. These complexes have potential applications in various fields, including catalysis, materials science, and medicinal chemistry, due to their unique properties and reactivity.
Used in Organic Synthesis:
As a reagent in organic synthesis, 2-Cyclohexyl-5-methyl-2H-pyrazol-3-ylamine is employed to facilitate various chemical reactions and transformations. Its presence can enhance the efficiency and selectivity of these reactions, leading to the production of desired organic compounds with potential applications in various industries.
Used in Biological Research and Drug Development:
2-Cyclohexyl-5-methyl-2H-pyrazol-3-ylamine is being studied for its potential biological activity, with the aim of identifying its therapeutic potential in treating certain health conditions. Its exploration in this area could lead to the discovery of new drugs and therapeutic agents, benefiting the medical and pharmaceutical sectors.

InChI:InChI=1/C10H17N3/c1-8-7-10(11)13(12-8)9-5-3-2-4-6-9/h7,9H,2-6,11H2,1H3

Upstream product

• 1118-61-2 3-Aminocrotononitrile 
• 6498-34-6 cyclohexylhydrazine 
• 24214-73-1 cyclohexylhydrazine hydrochloride 
• 108-94-1 cyclohexanone 
• 60295-21-8 N'-cyclohexyl-hydrazine carboxylic acid tert-butyl ester 
• 60295-11-6 tert-butyl 2-cyclohexylidenehydrazine-1-carboxylate 
• 2469-99-0 Cyanoaceton 

Downstream Products

• 1027293-98-6 4-chloro-1-cyclohexyl-3-methyl-1H-pyrazolo[3,4-b]pyridine-5-carbonyl chloride 
• 1027978-60-4 4-chloro-1-cyclohexyl-3-methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 
• 851520-97-3 4-chloro-1-cyclohexyl-3-methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid amide 
• 1027160-55-9 4-chloro-1-cyclohexyl-3-methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

Discovery, synthesis and biological characterization of a series of: N -(1-(1,1-dioxidotetrahydrothiophen-3-yl)-3-methyl-1 H -pyrazol-5-yl)acetamide ethers as novel GIRK1/2 potassium channel activators

The present study describes the discovery and characterization of a series of N-(1-(1,1-dioxidotetrahydrothiophen-3-yl)-3-methyl-1H-pyrazol-5-yl)acetamide ethers as G protein-gated inwardly-rectifying potassium (GIRK) channel activators. From our previous lead optimization efforts, we have identified a new ether-based scaffold and paired this with a novel sulfone-based head group to identify a potent and selective GIRK1/2 activator. In addition, we evaluated the compounds in tier 1 DMPK assays and have identified compounds that display nanomolar potency as GIRK1/2 activators with improved metabolic stability over the prototypical urea-based compounds. This journal is

Oxidative Ring-Opening of 1H-Pyrazol-5-amines and Its Application in Constructing Pyrazolo–Pyrrolo–Pyrazine Scaffolds by Domino Cyclization

Herein, an oxidative ring-opening of 1H-pyrazol-5-amines to form 3-diazenylacrylonitrile derivatives under mild and transition-metal-free conditions is described. In addition, the nucleophilic addition of deprotonated 1H-pyrrole-2-carbaldehydes to the vinyl moiety of the yielded 3-diazenylacrylonitriles could trigger domino cyclization to afford the 3H-pyrazolo[3,4-e]pyrrolo[1,2-a]pyrazine derivatives. Computational studies suggest that the oxidation of 1H-pyrazol-5-amines in the presence of PhIO is through the formation of a hydroxylamine intermediate followed by elimination of H2O to result in the ring-opening product. The detailed domino cyclization pathway leading to the pyrazolo–pyrrolo–pyrazine scaffolds is revealed.

HDAC inhibitor and preparation method and application thereof

The present invention discloses a compound represented by a formula I, a stereoisomer thereof, and a pharmaceutically acceptable salt thereof. The invention further relates to a pharmaceutical composition containing the compound shown in the formula I and application of the compound in preparation of HDAC inhibitor drugs. The compound or the pharmaceutical composition thereof can be used for treating cell proliferation diseases, autoimmune diseases, inflammation, neurodegenerative diseases or viral diseases.

Discovery, synthesis and characterization of a series of (1-alkyl-3-methyl-1H-pyrazol-5-yl)-2-(5-aryl-2H-tetrazol-2-yl)acetamides as novel GIRK1/2 potassium channel activators

The present study describes the discovery and characterization of a series of 5-aryl-2H-tetrazol-3-ylacetamides as G protein-gated inwardly-rectifying potassium (GIRK) channels activators. Working from an initial hit discovered during a high-throughput screening campaign, we identified a tetrazole scaffold that shifts away from the previously reported urea-based scaffolds while remaining effective GIRK1/2 channel activators. In addition, we evaluated the compounds in Tier 1 DMPK assays and have identified a (3-methyl-1H-pyrazol-1-yl)tetrahydrothiophene-1,1-dioxide head group that imparts interesting and unexpected microsomal stability compared to previously-reported pyrazole head groups.

Discovery and Characterization of 1H-Pyrazol-5-yl-2-phenylacetamides as Novel, Non-Urea-Containing GIRK1/2 Potassium Channel Activators

The G protein-gated inwardly-rectifying potassium channels (GIRK, Kir3) are a family of inward-rectifying potassium channels, and there is significant evidence supporting the roles of GIRKs in a number of physiological processes and as potential targets for numerous indications. Previously reported urea containing molecules as GIRK1/2 preferring activators have had significant pharmacokinetic (PK) liabilities. Here we report a novel series of 1H-pyrazolo-5-yl-2-phenylacetamides in an effort to improve upon the PK properties. This series of compounds display nanomolar potency as GIRK1/2 activators with improved brain distribution (rodent Kp > 0.6).

PYRAZOLOPYRIMIDINES AS INHIBITORS OF GLUCOCORTICOID RECEPTOR TRANSLOCATION

Provided herein are compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of Glucocorticoid Receptor (GR) translocation. Furthermore, the subject compounds and compositions are useful for the treatment of diseases involved in the hypothalamic-pituitary-adrenal (HPA) axis.

Identification and optimization of substituted 5-aminopyrazoles as potent and selective adenosine A1 receptor antagonists

Potent and selective adenosine A1 receptor antagonists were disclosed. SAR and pharmacological profile of selected compounds were discussed.

Discovery of new orally active phosphodiesterase (PDE4) inhibitors

A series of 4-anilinopyrazolopyridine derivatives were synthesized and biologically evaluated as inhibitors of phosphodiesterase (PDE4). Chemical modification of 3, a structurally new chemical lead that was found in our in-house library, was focused on 1- and 3-substituents. Full details of the discovery of a new orally active chemical lead 5 are presented. Structure-activity relationship data, pharmacological evaluation, and the subtype selectivity study are also presented.